A Phase 1 trial for TTI-622 with dose escalation and expansion phase focused on combination treatment

Trial Profile

A Phase 1 trial for TTI-622 with dose escalation and expansion phase focused on combination treatment

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs TTI 622 (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Trillium Therapeutics Inc
  • Most Recent Events

    • 01 Jun 2017 According to a Trillium Therapeutics Inc. media release, an Investigational New Drug (IND) application for TTI-662 combination therapy is targeted for the second half of 2017.
    • 01 Jun 2017 Indications are assumed based on RDI profile. Subjects are assumed as an adult patients and gender as male & female.
    • 01 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top